CY1570A - Crystal modification of disodium-3-amino-1-hydroxypropane-1,1-diphosphonate - Google Patents

Crystal modification of disodium-3-amino-1-hydroxypropane-1,1-diphosphonate

Info

Publication number
CY1570A
CY1570A CY1570A CY157091A CY1570A CY 1570 A CY1570 A CY 1570A CY 1570 A CY1570 A CY 1570A CY 157091 A CY157091 A CY 157091A CY 1570 A CY1570 A CY 1570A
Authority
CY
Cyprus
Prior art keywords
diphosphonate
hydroxypropane
disodium
amino
crystal modification
Prior art date
Application number
CY1570A
Other languages
English (en)
Original Assignee
Ciba Geigy Ag
Henkel Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4263070&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ciba Geigy Ag, Henkel Kgaa filed Critical Ciba Geigy Ag
Publication of CY1570A publication Critical patent/CY1570A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
    • C07F9/165—Esters of thiophosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839—Polyphosphonic acids
    • C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY1570A 1984-08-06 1991-12-20 Crystal modification of disodium-3-amino-1-hydroxypropane-1,1-diphosphonate CY1570A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH376884 1984-08-06

Publications (1)

Publication Number Publication Date
CY1570A true CY1570A (en) 1991-12-20

Family

ID=4263070

Family Applications (1)

Application Number Title Priority Date Filing Date
CY1570A CY1570A (en) 1984-08-06 1991-12-20 Crystal modification of disodium-3-amino-1-hydroxypropane-1,1-diphosphonate

Country Status (26)

Country Link
US (2) US4639338A (h)
EP (1) EP0177443B1 (h)
JP (1) JPS6143196A (h)
KR (1) KR940000817B1 (h)
AR (4) AR240832A1 (h)
AT (1) ATE47396T1 (h)
AU (1) AU591066B2 (h)
CA (1) CA1255694A (h)
CY (1) CY1570A (h)
DD (1) DD239597A5 (h)
DE (1) DE3573783D1 (h)
DK (1) DK167282B1 (h)
DO (1) DOP1990004769A (h)
ES (2) ES8701188A1 (h)
FI (1) FI79712C (h)
GR (1) GR851910B (h)
HK (1) HK42591A (h)
HU (1) HU193124B (h)
IE (1) IE58077B1 (h)
IL (1) IL75990A (h)
MX (1) MX9203373A (h)
NO (1) NO165401C (h)
PH (1) PH24854A (h)
PT (1) PT80916B (h)
SG (1) SG91390G (h)
ZA (1) ZA855892B (h)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH664158A5 (fr) * 1984-07-18 1988-02-15 Symphar Sa Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant.
DE3770982D1 (de) * 1986-04-24 1991-08-01 Fujisawa Pharmaceutical Co Diphosphonsaeure-verbindungen, verfahren zu deren herstellung und sie enthaltende arzneimittel.
US4963681A (en) * 1987-07-06 1990-10-16 Norwich Eaton Pharmaceuticals, Inc. Process for synthesis of aminomethylene phosphonoalkylphosphinates
IL86951A (en) * 1987-07-06 1996-07-23 Procter & Gamble Pharma Methylene phosphonoalkylphosphinates and pharmaceutical preparations containing them
IT1222734B (it) * 1987-09-25 1990-09-12 Scalvo S P A Formulaziopne farmaceutiche e forme di dosaggio per la somminaistarzione rettale di calcitonina
PH26923A (en) * 1989-03-08 1992-12-03 Ciba Geigy N-substituted amino alkanediphosphonic acids
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
PH27186A (en) * 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
EP0541037A3 (en) * 1991-11-06 1997-02-26 Takeda Chemical Industries Ltd Squalene synthetase inhibitory composition and use thereof
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
TW237386B (h) 1992-04-15 1995-01-01 Ciba Geigy
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
JP3266395B2 (ja) * 1993-11-24 2002-03-18 富士写真フイルム株式会社 有機薬品の晶析方法
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
GB9408775D0 (en) * 1994-05-04 1994-06-22 Ciba Geigy Ag Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
DE19719680A1 (de) 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
DE69827079T2 (de) * 1997-07-15 2005-09-08 Gador S.A. Kristalline Form von N,N-dimethyl-3-amino-1-hydroxypropan-1,1-Diphosphonsäure Mononatriumsalz Monohydrat und ein Verfahren zu ihrer Herstellung
EP1702924A3 (en) * 1998-08-27 2007-07-18 Teva Pharmaceutical Industries Ltd Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP1107974B1 (en) * 1998-08-27 2006-08-02 Teva Pharmaceutical Industries Ltd. Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
EP0998933A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Verfahren zur Herstellung von bisphosphonathaltigen pharmazeutischen Zusammensetzungen zur oralen Applikation
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
US6160165A (en) 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6794536B1 (en) * 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
ATE238315T1 (de) * 1998-12-10 2003-05-15 Aesgen Inc Verfahren zur herstellung von dinatriumpamidronat
US6315566B1 (en) 1999-05-18 2001-11-13 3M Innovative Properties Company Dental materials
US6143919A (en) * 1999-05-18 2000-11-07 3M Innovative Properties Company Polymerizable acidic compounds and methods of preparation
US6963008B2 (en) * 1999-07-19 2005-11-08 Teva Pharmaceutical Industries Ltd. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
ES2153794B1 (es) * 1999-08-06 2001-10-16 Medichem Sa Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
KR100343232B1 (ko) * 1999-12-10 2002-07-10 김재윤 결정성 파미드론산 이나트륨염 수화물과 그의 제조방법
WO2003079972A2 (en) 2002-02-22 2003-10-02 New River Parmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
KR20030043931A (ko) * 2000-09-18 2003-06-02 에프. 에이취. 펄딩 앤드 컴파니 리미티드 디포스포네이트 용액
ES2243457T3 (es) * 2001-01-23 2005-12-01 Gador S.A. Composicion que comprende bifosfonatos para la prevencion y/o tratamiento de trastornos metabolicos de huesos, procedimiento de preparacion de dicha composicion y usos de la misma.
EE200300477A (et) 2001-05-02 2003-12-15 Sicor, Inc. Süstitav pamidronaatdinaatrium
CA2347330C (en) * 2001-05-10 2002-03-12 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
ITMI20012751A1 (it) * 2001-12-21 2003-06-21 Lyogen Ltd Sale monosodico dell'acido pamidronico e procedimento per la sua preparazione
US20040052843A1 (en) * 2001-12-24 2004-03-18 Lerner E. Itzhak Controlled release dosage forms
NZ534104A (en) * 2001-12-24 2007-03-30 Teva Pharma Dosage form with a core tablet of active ingredient sheathed in a compressed annular body of powder or granular material
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
RU2315603C2 (ru) * 2002-12-20 2008-01-27 Ф.Хоффманн-Ля Рош Аг Композиция с высокой дозой ибандроната
US20050119230A1 (en) * 2003-09-18 2005-06-02 Alexandra Glausch Pharmaceutical products comprising bisphosphonated
EP1689759B1 (en) * 2003-12-04 2016-07-13 Mustafa Nevzat Ilac Sanayii A.S. Method for producing pure disodium pamidronate
KR101411117B1 (ko) 2004-05-24 2014-06-25 워너 칠콧 컴퍼니 엘엘씨 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
US7358361B2 (en) * 2004-10-08 2008-04-15 The Board Of Trustees Of The University Of Illinois Biophosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
WO2008128056A1 (en) * 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
KR20080111070A (ko) * 2006-03-17 2008-12-22 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 비스포스포네이트 화합물 및 방법
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
EP2234608A2 (en) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
PL2473172T3 (pl) 2009-09-01 2015-08-31 Univ Duke Kompozycje bisfosfonianowe i sposoby do leczenia niewydolności serca
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
MX2012012050A (es) 2010-04-16 2012-11-22 Novartis Ag Metodos y composiciones para mejorar la oseointegracion de implantes.
CN104010647A (zh) 2011-11-16 2014-08-27 杜克大学 用于治疗和/或减轻心功能障碍的双膦酸盐组合物及方法
GB201200868D0 (en) 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US20130303486A1 (en) * 2012-05-14 2013-11-14 Herriot Tabuteau Compositions Comprising Zoledronic Acid or Related Compounds for Relieving Pain Associated with Arthritis
KR101995432B1 (ko) * 2016-10-13 2019-07-02 엘지전자 주식회사 공기조화기 및 그 제어방법
EP3553067A1 (en) * 2018-04-10 2019-10-16 Abiogen Pharma S.p.A. Polymorph of sodium neridronate and preparation process thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2130794C3 (de) * 1971-06-22 1974-07-11 Joh. A. Benckiser Gmbh, 6700 Ludwigshafen Verfahren zur Herstellung von l-Hydroxy-S-amino-propan-ljl-diphosphonsäure
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
DE2534391C2 (de) * 1975-08-01 1983-01-13 Henkel KGaA, 4000 Düsseldorf 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren
JPS5283957A (en) * 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
DE2553963A1 (de) * 1975-12-01 1977-06-08 Henkel & Cie Gmbh Pharmazeutische praeparate zur behandlung von stoerungen des calciumstoffwechsels
DK506476A (da) * 1975-12-01 1977-06-02 Henkel & Cie Gmbh Farmaceutiske preparater til behandling af calciumstofs skifteforstyrrelser
SE409706B (sv) * 1976-05-21 1979-09-03 Astra Pharma Prod Forfarande for framstellning av n,n-dimetyl-3-(4-bromfenyl)-3-3(3-pyridyl)-allylamin dihydroklorid monohydrat
DE2702631A1 (de) * 1977-01-22 1978-07-27 Henkel Kgaa Verfahren zur herstellung von 1-hydroxy-3-amino-propan-1,1-diphosphonsaeuren
DE2943498C2 (de) * 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
DE3016289A1 (de) * 1980-04-28 1981-10-29 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von omega -amino-1-hydroxyalkyliden-1,1-bis-phosphonsaeuren
US4304734A (en) * 1980-10-16 1981-12-08 Vysoka Skola Chemicko-Technologicka 6-Amino-1-hydroxyhexylidene diphosphonic acid, salts and a process for production thereof
DE3151038A1 (de) * 1981-12-23 1983-07-28 Henkel KGaA, 4000 Düsseldorf Verfahren zur herstellung von 3-amino-1-hydroxypropan-1,1-diphosphonsaeure
US4446052A (en) * 1982-05-17 1984-05-01 The Procter & Gamble Company Aqueous gel containing tricalcium di(1-hydroxy-3-aminopropane-1,1-diphosphonate
CH664158A5 (fr) * 1984-07-18 1988-02-15 Symphar Sa Derives propylidenediphosphonates-1,3 substitues en position 2, leur procede de preparation et compositions pharmaceutiques les contenant.

Also Published As

Publication number Publication date
ES8701188A1 (es) 1986-11-16
AU4577785A (en) 1986-02-13
DOP1990004769A (es) 1999-08-19
AU591066B2 (en) 1989-11-30
HU193124B (en) 1987-08-28
NO165401B (no) 1990-10-29
NO853087L (no) 1986-02-07
DK355485D0 (da) 1985-08-05
ZA855892B (en) 1986-03-26
SG91390G (en) 1991-01-18
PT80916A (en) 1985-09-01
ES555602A0 (es) 1987-07-01
US4711880A (en) 1987-12-08
FI79712B (fi) 1989-10-31
KR860001821A (ko) 1986-03-22
GR851910B (h) 1985-12-03
PT80916B (pt) 1987-12-30
AR240832A2 (es) 1991-02-28
AR244696A1 (es) 1993-11-30
EP0177443A1 (de) 1986-04-09
HK42591A (en) 1991-06-07
FI79712C (fi) 1990-02-12
IL75990A (en) 1989-07-31
IE58077B1 (en) 1993-06-30
DE3573783D1 (en) 1989-11-23
IE851931L (en) 1986-02-06
ES545899A0 (es) 1986-11-16
HUT38361A (en) 1986-05-28
AR244698A1 (es) 1993-11-30
NO165401C (no) 1991-02-06
DK355485A (da) 1986-02-07
MX9203373A (es) 1992-09-01
EP0177443B1 (de) 1989-10-18
DD239597A5 (de) 1986-10-01
US4639338A (en) 1987-01-27
AR240832A1 (es) 1991-02-28
JPS6143196A (ja) 1986-03-01
ES8706707A1 (es) 1987-07-01
ATE47396T1 (de) 1989-11-15
FI852986L (fi) 1986-02-07
JPH058717B2 (h) 1993-02-02
CA1255694A (en) 1989-06-13
PH24854A (en) 1990-12-26
KR940000817B1 (ko) 1994-02-02
DK167282B1 (da) 1993-10-04
AR244697A1 (es) 1993-11-30
FI852986A0 (fi) 1985-08-02

Similar Documents

Publication Publication Date Title
DE3573783D1 (en) Crystal modification of disodium-3-amino-1-hydroxy-propane-1,1-diphosphonate
US4569280B1 (en) Produce wedger
GB2163353B (en) Osteotome
GB8522402D0 (en) Susceptor
GB8514053D0 (en) Diaper
GB2154885B (en) Traction splint
GB8530486D0 (en) Modulators
GB8429201D0 (en) Alignment aid
GB8507346D0 (en) Watch
GB8529069D0 (en) Orthosis
GB2162663B (en) Timepiece
AU95743S (en) Telelphone set
GB8415778D0 (en) Bandage
GB2153700B (en) Crystal growth
GB8507795D0 (en) Exo-skeletal splint
GB8420277D0 (en) Enuretic aid
GB8411079D0 (en) Modulators
GB8418290D0 (en) Clock
GB8417399D0 (en) Bandages
CS867284A1 (en) Sposob stanovenia obsahu n nitrozodimetylaminu
GB8423553D0 (en) Clocks
KR860002416Y1 (en) Clock
KR860003538Y1 (en) Aperpetual calendars
KR870001200Y1 (en) Watch
ZA855744B (en) Bandage